Inhibition of the upregulated phosphodiesterase 4D isoforms improves SERCA2a function in diabetic cardiomyopathy
British Journal of Pharmacology · 2025-04 · 182 (7) · 1487-1507
DOI: 10.1111/bph.17411 ↗At a glance
Journal article in British Journal of Pharmacology, published online on 2024-12-11. Written by Zhenduo Zhu and 11 co-authors. Institution: Key Laboratory of Anti-inflammatory and Immune Medicine, Ministry of Education; Collaborative Innovation Center of Anti-inflammatory and Immune Medic…. Major MEDLINE topics: Sarcoplasmic Reticulum Calcium-Transporting ATPases, Cyclic Nucleotide Phosphodiesterases, Type 4, Diabetic Cardiomyopathies, Phosphodiesterase 4 Inhibitors. Cited 7 times so far (Crossref); 66 references. The full text is freely available (open access, CC BY 4.0). Funded by: NHLBI NIH HHS, BLRD VA, National Institute of Health grant.
Abstract (original language)
Background and Purpose Sarcoplasmic reticulum Ca 2+ ‐ATPase (SERCA2a) is impaired in heart failure. Phosphodiesterases (PDEs) are implicated in the modulation of local cAMP signals and protein kinase A (PKA) activity essential for cardiac function. We characterise PDE isoforms that underlie decreased activities of SERCA2a and reduced cardiac contractile function in diabetic cardiomyopathy. Experimental Approach Wild type mice were fed with either normal chow or a high‐fat diet (HFD). Cardiomyocytes were isolated for excitation–contraction coupling (ECC), fluorescence resonant energy transfer PKA biosensor and proximity ligation assays. Key Results The upregulated PDE4D3 and PDE4D9 isoforms in HFD cardiomyocytes specifically bound to SERCA2a but not ryanodine receptor 2 (RyR2) on the sarcoplasmic reticulum (SR). The increased association of PDE4D isoforms with SERCA2a in HFD cardiomyocytes led to reduced local PKA activities and phosphorylation of phospholamban (PLB) but minimally effected the PKA activities and phosphorylation of RyR2. These changes correlate with slower calcium decay tau in the SR and attenuation of ECC in HFD cardiomyocytes. Selective inhibition of PDE4D3 or PDE4D9 restored PKA activities and phosphorylation of PLB at the SERCA2a complex, recovered calcium decay tau, and increased ECC in HFD cardiomyocytes. Therapies with PDE4 inhibitor roflumilast , PDE4D inhibitor BPN14770 or genetical deletion of PDE4D restored PKA phosphorylation of PLB and cardiac contractile function. Conclusion and Implications The current study identifies upregulation of specific PDE4D isoforms that selectively inhibit SERCA2a function in HFD‐induced cardiomyopathy, indicating that this remodelling can be targeted to restore cardiac contractility in diabetic cardiomyopathy.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Key Laboratory of Anti-inflammatory and Immune Medicine, Ministry of Education; Collaborative Innovation Center of Anti-inflammatory and Immune Medicine, Institute of Clinical Pharmacology, Anhui Medical University, Hef…
- Department of Pharmacology, University of California, Davis, Davis, California, USA.
- Department of Veterans Affairs Northern California Healthcare System, Mather, California, USA.
- School of Pharmaceutical Sciences and the Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou, China.
- Department of Cardiology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.
- Department of Emergency Medicine, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
ORCID profiles: Wei Wei, Qingtong Wang, Yang K Xiang
Funding
- NHLBI NIH HHS
- BLRD VA
- National Institute of Health grant
- National Natural Science Foundation of China
- Anhui Province Excellent Research and Innovation Team Project
- VA Merit grant
- Postgraduate Innovation Research and Practice Program of Anhui Medical University
Cite
APA
Zhu, Z., Guan, Q., Xu, B., Bahriz, S., Shen, A., West, T. M., Zhang, Y., Deng, B., Wei, W., Han, Y., Wang, Q., & Xiang, Y. K. (2025). Inhibition of the upregulated phosphodiesterase 4D isoforms improves SERCA2a function in diabetic cardiomyopathy. British Journal of Pharmacology, 182(7), 1487-1507. https://doi.org/10.1111/bph.17411
Vancouver
Zhu Z, Guan Q, Xu B, Bahriz S, Shen A, West TM, et al. Inhibition of the upregulated phosphodiesterase 4D isoforms improves SERCA2a function in diabetic cardiomyopathy. British Journal of Pharmacology. 2025;182(7):1487-1507. doi:10.1111/bph.17411
BibTeX
@article{Zhu2025,
author = {Zhu, Zhenduo and Guan, Qiuyun and Xu, Bing and Bahriz, Sherif and Shen, Ao and West, Toni M and Zhang, Yu and Deng, Bingqing and Wei, Wei and Han, Yongsheng and Wang, Qingtong and Xiang, Yang K},
title = {Inhibition of the upregulated phosphodiesterase 4D isoforms improves SERCA2a function in diabetic cardiomyopathy},
journal = {British Journal of Pharmacology},
year = {2025},
volume = {182},
number = {7},
pages = {1487--1507},
doi = {10.1111/bph.17411}
}
EUVIMED